Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115595 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Daniela Scattolin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova…. Hauptthemen laut MEDLINE: Carbolines, Heterocyclic Compounds, 4 or More Rings, Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Lurbinectedin has recently emerged in the treatment landscape of extensive stage (ES) small cell lung cancer (SCLC). Here we report the outcomes and safety of lurbinectedin within a named patient program in a multicentric, international cohort. METHODS: Clinical data of all patients with ES-SCLC treated with lurbinectedin at the Erasmus Medical Center (EMC, Rotterdam-The Netherlands) and the Veneto Institute of Oncology (IOV, Padua-Italy) were collected. RESULTS: A total of 238 patients receiving lurbinectedin as second- (37 %), third- (45 %) or further-line (18 %) were included. Median number of cycles was 3 (1-22). The objective response rate was 23.1 %, the disease control rate 45.5 %. The median progression free survival (PFS) 2.2 months (95 %CI 1.6-2.8) and the median overall survival (OS) 5.4 months (95 %CI 4.5-6.3). Patients with a chemotherapy-free interval (CFI) ≥ 90 days showed a longer PFS (3.1 vs 1.8 months, HR 0.46, 0.30-0.71, p < 0.001) and OS (6.8 vs 4.5 months, HR 0.56, 0.37-0.85, p = 0.006). Patients with ECOG performance status (PS) ≥ 2 at lurbinectedin start, brain or liver metastasis showed a worse outcome. Adverse events were recorded in 218 (92 %) patients, with 29 % grade 3-4 events. CONCLUSION: Considering its safety profile and modest but consistent effectiveness, lurbinectedin represents a therapeutic option as compassionate use in patients with ES-SCLC, especially in those with a long CFI. Poor PS, CFI < 90 days, brain or liver metastases may affect the OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Department of Respiratory Medicine, Erasmus MC Cancer…
- Department of Respiratory Medicine, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands.
- Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
- Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
- Department of Respiratory Medicine, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands. Electronic address: d.dumoulin@erasmusmc.nl.
Zitieren
APA
Scattolin, D., Dingemans, A. C., Maso, A. D., Guarneri, V., Aerts, J. G. J. V., Pasello, G., & Dumoulin, D. W. (2025). Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115595
Vancouver
Scattolin D, Dingemans AC, Maso AD, Guarneri V, Aerts JGJV, Pasello G, et al. Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115595
BibTeX
@article{Scattolin2025,
author = {Scattolin, Daniela and Dingemans, Anne-Marie C and Maso, Alessandro Dal and Guarneri, Valentina and Aerts, Joachim G J V and Pasello, Giulia and Dumoulin, Daphne W},
title = {Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115595}
}
EUVIMED